Evicenter
P&T meetings

Bezuclastinib

Gastrointestinal stromal tumor

Manufacturer
Cogent Biosciences
Regulatory submission
NDA submitted April 2026
Last updated
76 sources

Product information and disease descriptionProduct description

Product information

19 evidence topics · 16 sources

Average sales price and wholesale acquisition cost

Not applicable.

Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions

Not applicable.

Effect of Bezuclastinib on quality measures

No evidence found.